The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Afexa Life Sciences

Monday Biotech Deal Review: November 14, 2011

Welcome to your Monday Biotech Deal Review for November 14, 2011, marking the end of its one month hiatus.  The Monday Biotech Deal Review will now be resuming its normal weekly schedule.  Below are summaries of recent transactions over the past month, which includes the acquisition of Afexa by Valeant for $0.85 per Afexa share, in cash.    Read on to learn more.  Read more of this post

Monday Biotech Deal Review: October 17, 2011

Welcome to your Monday Biotech Deal Review for October 17, 2011.  This week’s deal review is a double feature following last Monday’s Canadian thanksgiving holiday.  Of note from the past two weeks were the acquisition of Labopharm by Paladin Labs, and its announcement that it is ceasing its hostile takeover pursuit of Afexa.  Read more of this post

Monday Biotech Deal Review: October 3, 2011

Welcome to your Monday Biotech Deal Review for October 3, 2011.  Last week witnessed a flurry of financing activity, with over $50M closed.  As well, the competing take-over bids between Paladin and Valeant for Afexa heated up with both Valeant and Paladin sweetening their offers to Afexa shareholders.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: September 26, 2011

Welcome to your Monday Biotech Deal Review for September 26, 2011.  Noteworthy news from last week included a hint that Labopharm will enhance its offer for the shares of Afexa Life Sciences if its two shareholder rights plans are waived or cease-traded by the ASC.  As well, Medicago announced a significant private placement for proceeds of up to $24.5M, and Valeant has announced its intention to refinance its secured credit facilities with a new $1.7bn facility.  Read more of this post

Monday Biotech Deal Review: September 19, 2011

Welcome to your Monday Biotech Deal Review for September 19, 2011.  Of note in the past week was the extension of the hostile bid by Paladin Labs of Afexa Life Sciences to September 28th, the application by Merus to graduate to the TSXV, and the filing by Allon Therapeutics of a short-form preliminary prospectus.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: September 12, 2011

Welcome to your Monday Biotech Deal Review for September 12, 2011.  We hope everyone had a restful labo(u)r day long weekend, both north and south of the border.  This week’s biotech deal review is a double feature owing to last week’s holiday.  There has been a lot of activity in the past two weeks, including the announcement of a friendly takeover bid of Afexa by Valeant (Afexa is already the target of a hostile bid by Paladin).  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: August 29, 2011

Welcome to your Monday Biotech Deal Review for August 29, 2011.  In addition to the usual private placement announcements and various commercial transactions, the ongoing hostile bid for Afexa Life Sciences was in the news, with the board of Afexa confirming its recommendation to shareholders to not tender their shares pursuant to the unsolicited bid by Paladin Labs.  Read on to learn more.   Read more of this post

Monday Biotech Deal Review: August 22, 2011

Welcome to your Monday Biotech Deal Review for August 22, 2011.  This week’s deal review is brought to you by Norton Rose OR LLP articling student Keldeagh Lindsay, who will be with us during his articles and assisting in the deal review.  Steven Zuccarelli has done a great job over the summer, and we wish him well in his final year at law school.  

There has been quite a lot of activity over the previous two weeks, with significant equity investment activity, debt financings (public and private), and mergers and acquisitions on the go.  Read on to learn more. Read more of this post

Monday Biotech Deal Review: July 25, 2011

Welcome to your Monday Biotech Deal Review for July 25, 2011.  Interesting tidbits from last week included the termination of the letter of intent relating to the proposed reverse-takeover transaction between Bradmer Pharmaceuticals and P1 Energy Corp., a distribution and marketing agreement between Valeant and Sanofi-aventis Canada, a $15M loan agreement between Protox Therapeutics and Oxford Finance LLC, the filing of a preliminary short-form base shelf prospectus in the Canada and U.S. by YM BioSciences, the closing of a $7M financing round for gIcare Pharma Inc., and the acquisition by Paladin Labs of a significant number of common shares of Afexa Life Sciences.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: January 24, 2010

Welcome to your Monday Biotech Deal Review for January 24, 2010.  Despite a slow financing week, there were a few operational announcements as well as awards granted to Canadian biotech companies by the NIH and the UK’s Medical Research Council.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: October 25, 2010

Welcome to your weekly review of Canadian biotech deals for October 25, 2010.  Last week’s notable transactions included the Qualifying Transaction of TSXV CPC company CCS Capital Inc. (now known as China Health Labs & Diagnostics Ltd.) and ProMetic’s strategic agreement with Allist Pharmaceuticals Inc., for the commercialization in China of two of ProMetic’s drug candidates.  Read on to learn more about these transactions, as well as the usual assortment of Canadian biotech news. Read more of this post

Monday Biotech Deal Review: August 9, 2010

Catching up from the long weekend last week, we have a full two weeks’ worth of deals to bring you. Highlights include $16.7 million of securities closings, $8.25 million launched; and interesting developments in the Forbes Medi-Tech and Northstar Healthcare acquisitions. Check out what the last two weeks have wrought… after the jump

Monday Biotech Deal Review: February 1, 2010

Canadian biotech companies were busy making and closing deals this week, with $44 million raised, four new licensing and collaboration deals, and particularly big weeks for Ospens and the MDS/Dahaner transaction. Read more of this post

Follow

Get every new post delivered to your Inbox.

Join 131 other followers